Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 445-453

  Liu, Jing ^a   Kraut, Eric H ^b   Balcerzak, Stanley ^b   Grever, Michael ^b   D'Ambrosio, Steven ^b   Chan, Kenneth K ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cremophor EL; Drug interaction; Paclitaxel; Pharmacokinetics; Platinum

Indexed keywords

ALCOHOL; CREMOPHOR; DRUG VEHICLE; OXALIPLATIN; PACLITAXEL; PLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; ERYTHROCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE; ULTRAFILTRATION; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; GLYCEROL; INFUSIONS, INTRAVENOUS; LEUKOCYTES; MALE; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0036449303     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0531-6     Document Type: Article

References (26)

1. Baker SK, Niazi S (1983) Simple reliable method for chronic cannulation of the jugular vein for pharmacokinetic studies in rats. J Pharm Sci 72:2027-2029
2. Blagosklonny MV, Fojo T (1999) Molecular effects of paclitaxel: Myths and reality (a critical review). Int J Cancer 83:151-156
3. Boughattas NA, Levi F, Fournier C, et al (1989) Circadian rhythm in toxicity and tissue uptake of 1,2-diamino-cyclohex-ane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 49:3362-3368
4. Chervinsky DS, Brecher ML, Baker RM, Hoelcle MJ, Tebbi CK (1993) Reversal of C1300 murine neuroblastoma multidrug resistance by Cremophor EL, a solvent for cyclosporin A. Cancer Biother 8:67-75
5. Cvitkovic E (1998) Ongoing and unsaid on oxaliplatin: The hope. Br J Cancer 77:8-11
6. Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15:109-114
7. Ellis AG, Crinis NA, Webster LK (1996) Inhibition of etoposide in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38:81-87
8. Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 [Suppl 5]:13-22
9. Frei E III, Elias A, Wheeler C, et al (1998) The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 4:2027-2037
10. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N (1995) Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 15:393-398
11. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915
12. Knemeyer I, Wientjes MG, Au JLS (1999) Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44:241-248
13. Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK (2002) Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 49:367-374
14. Luo FR, Wyrick SD, Chaney SG (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19-28
15. Manfredi JJ, Horwitz SB (1984) Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther 25:83-125
16. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976
17. Raymond E, Faivre S, Woynarowski JM, et al (1998) Oxa-liplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25 [2 Suppl 5]:4-12
18. Riccardi A, Meco D, Lasarella A, et al (1997) Comparison of cytotoxicity of oxaliplatin, cisplatin and carboplatin in human neuroblastoma (NB) cell lines. Proc Am Soc Clin Oncol 16:A249
19. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865
20. Rowinsky EK, Donehower RC (1995) Drug therapy: Paclitaxel. N Engl J Med 332:1004-1014
21. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D (1994) Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248
22. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA (1992) Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267:24995-25002
23. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 59:1454-1457
24. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice result from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115
25. Webster LK, Cosson EJ, Stokes KH, Millward MJ (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73:522-524
26. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH (1992) Reversal of multidrug resistance by surfactants. Br J Cancer 66:62-68